Vipin Garg, Altimmune CEO
Altimmune’s fate turns around after longer look at obesity trial
Altimmune said a high dose of its weight loss injectable pemvidutide led to mean weight loss of 15.6% at week 48 in a Phase II …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
